W. C. Van Voorhis

This paper evaluates a novel antiglycolytic compound, BKIDC-1553, showing selective growth inhibition of prostate cancer cells and safety for clinical trials.

The paper examines structural changes in the SARS-CoV-2 spike E406W mutant that reduce neutralization by a monoclonal antibody cocktail and alters epitope recognition.

This study investigates how delta and kappa SARS-CoV-2 variants evade immune responses by altering antigenic sites and reducing ACE2 binding affinity.

This study shows that vaccines encoding a prefusion-stabilized SARS-CoV-2 spike protein induce higher neutralizing antibody titers and better variant cross-neutralization compared to other vaccines or infection.

This study evaluates how the B.1.427/B.1.429 SARS-CoV-2 variant evades neutralizing antibodies through mutations in the RBD and NTD, showing reduced neutralization by both vaccine-induced and infection-derived antibodies.

This study shows that a SARS-CoV-2 RBD nanoparticle vaccine protects against SARS-CoV-2 and related sarbecoviruses, including variants, in mice and non-human primates.

The paper screens drug libraries to find inhibitors of SARS-CoV-2 nsp15 endoribonuclease, identifying Exebryl-1 as a potential antiviral compound.

This study characterizes the enzymatic properties and structure of Naegleria fowleri glucokinase, identifying potential inhibitors for therapeutic development against the parasite.